Raul Cordoba

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 160 publications

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 15, 2026

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal: Circulation

Published: June 15, 2026

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal: Journal for immunotherapy of cancer

Published: June 10, 2026

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Haematology

Published: March 31, 2026

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Journal: Blood

Published: March 25, 2026

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers.

Journal: The Lancet. Haematology

Published: February 18, 2026

Mapping the capacity for geriatric blood Cancer Care in Latin America: A cross- sectional survey of current status and future priorities.

Mapping the capacity for geriatric blood Cancer Care in Latin America: A cross- sectional survey of current status and future priorities.

Journal: Journal of geriatric oncology

Published: February 13, 2026

Navigating the cardiovascular seas after allogeneic stem cell transplantation: charting a course for prevention.

Navigating the cardiovascular seas after allogeneic stem cell transplantation: charting a course for prevention.

Journal: European journal of preventive cardiology

Published: January 28, 2026

Development of lymphomatoid papulosis during brentuximab vedotin treatment: a paradoxical phenomenon.

Development of lymphomatoid papulosis during brentuximab vedotin treatment: a paradoxical phenomenon.

Journal: Leukemia & lymphoma

Published: January 28, 2026

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study.

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study.

Journal: JACC. CardioOncology

Published: January 15, 2026

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data.

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data.

Journal: Clinical pharmacology and therapeutics

Published: November 08, 2025

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Journal: British journal of haematology

Published: November 03, 2025

Showing 1-12 of 160

Last Updated: 09/26/2026